Skip to main content

Table 3 Causes of death

From: Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

 

FT

TBF

FLAMSA

Total

75

67

410

Hemorrhage

2 (3%)

2 (3%)

4 (1%)

Failure/rejection

1 (2%)

0 (0%)

2 (1%)

Infection

11 (16%)

18 (27%)

73 (19%)

Interstitial pneumonitis

1 (1%)

2 (3%)

6 (2%)

GVHD

7 (10%)

7 (10%)

31 (8%)

Original disease

40 (59%)

27 (40%)

244 (63%)

VOD

0 (0%)

4 (6%)

8 (2%)

Other transplantation related

5 (7%)

7 (10%)

18 (5%)

Missing

7

0

21

  1. FLAMSA fludarabine, intermediate dose Ara-C, amsacrine, total body irradiation, cyclophosphamide sequential regimen, FT fludarabine-treosulfan, GVHD graft-versus-host disease, TBF thiotepa-busulfan-fludarabine, VOD veno-occlusive disease